OR WAIT null SECS
Scientists are leveraging ddPCR technology to get an accurate read on viral titer and vector copy number.
Cell and gene therapies (CGTs) can potentially treat, and sometimes even cure, a wide range of genetic and acquired diseases ranging from immunodeficiencies to cancer. For this reason, the field has been growing at an astronomical rate. Having impeccable data about the makeup of a new therapeutic is vital to successful clinical trials that take a new drug candidate one step closer to FDA approval. But the myriad designs of CGTs in development today make that uniquely challenging. In this article, the author will explore some of the specific hurdles associated with lentiviral CGTs.
Marwan Alsarraj is biopharma segment manager, Digital Biology Group, Bio-Rad.
eBook: Emerging Therapies
When referring to this article, please cite it as Alsarraj, M. Navigating the Intricacies of Lentiviral CGTs. BioPharm International’s Emerging Therapies eBook. September 2023.